Pancreatic cancer is one of the solid tumors with the worst prognosis. Five-year survival rate
is less than 10%. Surgical resection is the only potentially curative treatment, but the tumor is …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal malignancy with a
high rate of recurrence and a dismal 5‐year survival rate. Contributing to the poor prognosis …

The efficiency of radiotherapy treatment regimes varies from tumour to tumour and from
patient to patient but it is generally highly influenced by the tumour microenvironment (TME) …

Background The prognostic and predictive value of carbohydrate antigen 19-9 (CA 19-9) in
locally advanced pancreatic cancer (LAPC) has not yet been defined from prospective …

Background In this era of increasing neoadjuvant chemotherapy, methods for evaluating
responses to neoadjuvant chemotherapy are still diverse among institutions. Additionally …

Simple Summary Gemcitabine/nab-paclitaxel (GN) and FOLFIRINOX (FFX) are two standard
first-line therapies for metastatic pancreatic cancer (PC) but have rarely been compared …

Current Opinion in Gastroenterology Log in or Register Subscribe to journalSubscribe Get new
issue alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle navigation …

Simple Summary This study is to examine the clinical and pathologic characteristics and
survival in patients who received neoadjuvant FOLFINOX or neoadjuvant gemcitabine/nab …

Pancreatic cancer has a dire prognosis and will represent the second leading cause of
cancer death in the next 10 years. The multifactorial approach represents one of the main …

Pancreatic cancer has traditionally been associated with a dismal prognosis, even in early
stages of the disease. In recent years, the introduction of newer generation chemotherapy …